# NMN (Nicotinamide Mononucleotide) and NAD+ in Aging Research

> NMN (Nicotinamide Mononucleotide) and NAD+ in aging research: the Mills mouse-aging study, the human trials raising blood NAD+ and muscle insulin sensitivity, and NMN's contested status. Cited.

The precursor one step from NAD+: the mouse-aging study that put it on the map, the human trials that raised blood NAD+, and the regulatory dispute around it — read straight.

## The gist

NMN (nicotinamide mononucleotide) is a precursor — a building block the body converts into NAD+ — and it sits just one biochemical step away from NAD+ itself. It became the headline NAD+ molecule because of a single mouse study: a full year of NMN slowed several signs of aging in old mice. In people, NMN reliably raises the NAD+ measured in blood and, in one trial, improved how well muscle responded to insulin. Its status is also contested — U.S. regulators have disputed whether NMN can be sold as a supplement. This page covers all of that as research, not advice, and never calls an NMN study 'taking NAD+'.

## What NMN is

NMN (nicotinamide mononucleotide, CAS `1094-61-7`) is a direct NAD+ precursor one biochemical step from NAD+: the salvage enzyme NMNAT converts NMN to NAD+ [5]. Taken orally, it is the precursor most associated with the aging-research story. Like NR, it carries an ORAL-PRECURSOR channel tag on this site — an NMN trial measures a precursor the body converts into NAD+, not NAD+ taken directly, which is poorly absorbed and not the same intervention [5]. Keeping that distinction exact is the whole point of the channel tagging here.

## The Mills mouse-aging study

The study that anchored NMN to aging is Mills and colleagues' 12-month experiment in mice. Long-term oral NMN at `100-300 mg/kg/day`, given in drinking water across a year, mitigated age-associated physiological decline across multiple tissues: it suppressed age-associated weight gain, enhanced energy metabolism, and improved insulin sensitivity, eye function and bone density, with no toxicity observed [13]. It is the clearest single demonstration that sustained NMN can blunt several aging phenotypes in a mammal. It is also, importantly, a mouse study — a PRECLINICAL result. The strongest anti-aging effects in the NAD+ field remain in rodents and may not extrapolate to humans [14].

## Human NMN trials: blood NAD+ and insulin sensitivity

The human NMN record is more measured but consistent on its core endpoint. In a randomized, multicenter, double-blind trial of healthy middle-aged adults, oral NMN at `300/600/900 mg/day` for 60 days raised blood NAD+ significantly at days 30 and 60 across all doses versus placebo (p<=0.001), improved six-minute walking distance and quality-of-life scores, and kept a biological-age measure from rising — with `600 mg/day` identified as optimal and no safety issues at any dose [3]. In a separate trial of prediabetic, postmenopausal women, `250 mg/day` of NMN for 10 weeks increased muscle insulin sensitivity by hyperinsulinemic-euglycemic clamp and remodeled insulin signaling, though without changing body composition or HbA1c [11]. Blood-NAD+ elevation is reproducible; the functional readouts are promising but were not uniform across every group and endpoint [14].

## The contested regulatory status of NMN

NMN occupies an unsettled spot in the U.S. marketplace. The FDA has taken the position that NMN is excluded from the dietary-supplement definition because it was authorized for investigation as a drug — a regulatory dispute that has created marketplace uncertainty about selling NMN as a supplement [13]. This is best understood as an ongoing marketplace and definitional dispute, not a finding that NMN is 'banned' or 'illegal'. Separately, NMN and the other NAD+ precursors (NR, nicotinamide) are not prohibited by WADA. This site reports that status as it stands; it does not sell NMN, advise on its purchase, or take a position on the dispute. Read these NMN findings alongside the [age-related NAD+ decline](/research) they are meant to address.

---

A signal-clean readout of the NAD+ literature — the precursor trials that actually moved whole-blood NAD+ logged in their own oral channel, plain oral NAD+ and the weak-evidence IV route kept on separate channels, and the unsettled NMN status reported as filed; no clinic behind this console and nothing here dosed, dispensed, or sold.